Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial

Abstract

This randomized clinical trial evaluates the use of atorvastatin combined with narrowband UV-B therapy vs narrowband UV-B therapy alone in adult patients with active vitiligo.

Figure 1.. Flowchart of the Study^a

Of the 30 patients randomized, 29 patients completed the study and were included in the modified intent-to-treat analysis (1 patient refused randomization and did not receive any treatment). NB-UV-B indicates narrowband UV-B phototherapy. ^aThe exact number of patients screened is unavailable and 150 is presented as an estimate. The inclusion criteria included patients aged 18 to 75 years, active nonsegmental vitiligo, and patient registered to French social security. The exclusion criteria included segmental or mixed vitiligo, allergy to statin medications, and use of statin or fibrate medications owing to cardiac risks.

Figure 2.. Evolution of Vitiligo Area Scoring Index (VASI) and Vitiligo European Task Force (VETF) Spreading Scores From Baseline to Each Study Visit

These results show no statistically significant difference in the mean VASI changes between the 2 groups and a significant decrease in the spreading of vitiligo 6 months after the 2 treatments, but no statistically significant difference between the 2 groups. Horizontal line in each box indicates the median. The diamond within each box indicates the mean. Top and bottom borders of the boxes indicate 75th and 25th percentiles. The whiskers that extend from each box indicate the range of values that are outside of the interquartile range, but are close enough not to be considered outliers (a distance less than or equal to ≤1.5 • IQR). Points beyond whiskers are outliers. NB-UV-B indicates narrowband UV-B phototherapy.